secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annexon, Inc. (ANNX)
CIK:        0001528115
Form:       8-K
Filed at:   2026-08-10T20:35:51+00:00
Accession:  0001193125-26-342524
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Annexon appoints Mark Blumenkranz to board; Muneer Satter steps down after 11 years
--------------------------------------------------------------------------------

- Mark S. Blumenkranz appointed to Annexon board effective Aug 10, 2026, as Class II director with term to 2028 annual meeting.
- He joins Audit Committee and Science and Technology Committee; receives $40k annual retainer and 175k-share initial option grant.
- Muneer Satter resigned as director and committee roles effective immediately prior to Blumenkranz appointment; no disagreement cited.
- Blumenkranz is Stanford emeritus professor; co-founded Adverum, Optimedica, Oculeve, Kedalion; retinal expertise relevant to vonaprument.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526342524/0001193125-26-342524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1528115/000119312526342524/d130710d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-342524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer